POTS patients may find relief from standing symptoms with moxonidine
NCT ID NCT04140721
First seen Mar 31, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study looks at whether moxonidine, a drug that lowers sympathetic nerve activity, can reduce symptoms like rapid heartbeat and lightheadedness in people with Postural Tachycardia Syndrome (POTS). About 48 women with POTS will take either moxonidine or a placebo for 4 weeks. The goal is to see if the drug improves how they feel when standing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTURAL TACHYCARDIA SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37221, United States
Conditions
Explore the condition pages connected to this study.